Valneva accelerates Lyme disease vaccine R&D project with Pfizer
pharmaphorum
DECEMBER 4, 2020
Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.
Let's personalize your content